Immunovative Therapies   Report issue

For profit Phase 2 Phase 3
Founded: Jerusalem Israel (2004)

Organization Overview

First Clinical Trial
2009
NCT00861107
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Immunovative Therapies, Ltd.